CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

The persistence or recurrence of minimal residual disease (MRD) after chemotherapy predicts relapse of B-cell acute lymphoblastic leukemia (B-ALL). CD19-directed chimeric antigen receptor T (CD19 CAR-T) cells have shown promising responses in B-ALL. However, their role in chemotherapy-refractory MRD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2021-12, Vol.70 (12), p.3501-3511
Hauptverfasser:	Lu, Wenyi, Wei, Yunxiong, Cao, Yaqing, Xiao, Xia, Li, Qing, Lyu, Hairong, Jiang, Yili, Zhang, Huan, Li, Xin, Jiang, Yanyu, Meng, Juanxia, Yuan, Ting, Zhu, Haibo, He, Xiaoyuan, Jin, Xin, Sun, Rui, Sui, Tao, Liu, Kaiqi, Zhao, Mingfeng
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Adolescent Adult Aged Antigens, CD19 - immunology Cancer Research CD19 antigen Chemotherapy Chimeric antigen receptors Clinical trials Cytokines Female Humans Immunology Immunotherapy, Adoptive - methods Lymphatic leukemia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma, B-Cell - immunology Male Medicine Medicine & Public Health Middle Aged Minimal residual disease Neoplasm, Residual - immunology Oncology Original Original Article Patients Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology Progression-Free Survival Receptors, Chimeric Antigen - immunology Recurrence Remission Remission (Medicine) T-Lymphocytes - immunology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!